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Abstract: The objective was to evaluate available literature on treatment of chronic pouchitis with
fecal microbiota transplantation (FMT) focusing on clinical outcomes, safety, and different approaches
to FMT preparation and delivery. A systematic review of electronic databases was conducted using
Medline, EMBASE, and the Cochrane Central Register of Controlled Trials Library from inception
through April 2020. Human studies of all study types reporting results of FMT to treat chronic
pouchitis were included. Nine studies, reporting FMT treatment of 69 patients with chronic pouchitis
were found eligible for the review. Most studies were case series and cohort studies rated as having
fair to poor quality due to high risk of bias and small sample size. Only one randomized controlled
trial was included, finding no beneficial effect of FMT. In total clinical response after FMT was reported
in 14 (31.8%) out of 44 evaluated patients at various timepoints after FMT, and clinical remission in
ten (22.7%) patients. Only minor self-limiting adverse events were reported. FMT varied greatly
regarding preparation, length of treatment, and route of delivery. The effects of FMT on symptoms of
chronic pouchitis are not established, though some studies show promising results. Future controlled
well-designed studies are warranted.
Keywords: pouchitis; fecal microbiota transplantation; microbiota; IPAA
1. Introduction
Restorative proctocolectomy with ileal pouch anal anastomosis (IPAA) is the surgical treatment
in patients with ulcerative colitis (UC) refractory to medicinal therapy, in some cases of colorectal
cancer and in familial adenomatous polyposis [1]. However, pouchitis occurs in up to 60% of the UC
patients after surgery [2,3]. Pouchitis is characterized by inflammation, mainly confined to the pouch,
with symptoms such as increased bowel movements, fever, bloody stool, fatigue, and abdominal
pain [2,4]. Pouchitis often develops as an acute, but transient, inflammation responding to antibiotics.
For 5% of patients, the inflammation becomes chronic, being antibiotic-dependent, with the need
of continuously antibiotic treatment, or refractory, not responding to the standard treatment with
antibiotics [5–7].
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The etiology of pouchitis remains unclear, but the gut microbiome is hypothesized as a key factor.
The pouch microbiome of patients with pouchitis is different compared to patients with a non-inflamed
pouch [8,9]. The dysbiotic microbiome of an acute or chronic inflamed pouch is characterized by
lowered bacterial diversity and changed abundance of certain bacteria [8,10–12]. Antibiotics can in
many cases relieve symptoms of pouchitis and the use of probiotics can decrease the risk of developing
pouchitis, further indicating the significance of the gut microbiome in pouchitis [12–14].
Pouchitis is usually treated with ciprofloxacin and/or metronidazole, which in case of chronic
pouchitis often fails [15]. Treatment of chronic pouchitis is challenging with limited therapeutic options,
potentially leading to the need for biological treatment or surgical removal of the ileal pouch [5–7].
Modification of the fecal microbiome in patients with chronic pouchitis has received increased
attention within recent years [16]. The positive results of treating recurrent Clostridioides difficile infection
(rCDI), with fecal microbiota transplantation (FMT) [17], and the promising results in inflammatory
bowel disease (IBD) [18,19], has led to the interest of inverting the gut dysbiosis of patients with chronic
pouchitis using FMT to potentially relieve symptoms.
Within recent years, several smaller studies have reported both positive and negative clinical
results of treating chronic pouchitis with FMT [20–23].
This systematic review aims to review the current literature on treatment of chronic pouchitis
with FMT focusing on clinical effects, safety and the different approaches to FMT treatment.
2. Methods
2.1. Search Strategy and Study Selection
This systematic review was performed in accordance with the PRISMA 2009 guidelines [24].
A literature search was performed using Medline (from 1948), EMBASE (from 1947), and the Cochrane
Central Register of Controlled Trials Library (for all years) through 15 April 2020. Bibliographies of
review articles and meta-analyses were searched to identify additional studies [8,25,26]. Furthermore,
the bibliography of the primary author of the included studies were reviewed to search for further
eligible publications. Web of Science [27] was used to identify additional potential publications that
have cited the included studies. Clinicaltrials.gov [28] and WHO International Clinical Trials Registry
Platform [29] were used to search for results from unpublished studies. To search for grey literature
opengrey.eu [30] was used. The detailed search strategy is outlined in the online Supplementary
Materials, Table S1.
Eligibility criteria for inclusion of studies were defined prior to the search through registration
of the research protocol in Prospero International Prospective Registry of Systematic Reviews
(CRD42020167258) [31]. Inclusion criteria were “human interventional studies using FMT of all study
types”, including randomized controlled trials, non-randomized controlled studies, cohort studies,
and case studies (case series and case reports), to “treat chronic pouchitis” (recurrent or antibiotic
refractory) “reporting clinical outcomes on pouch symptoms”. Studies including “participants of
all ages” were included. The search was restricted to studies written in or translated to English.
In controlled studies, the accepted comparator was either placebo, autologous FMT, or no treatment.
Data presented as a conference abstract were also accepted. Exclusion criteria were studies where FMT
was given as primary treatment to treat other conditions than chronic pouchitis.
All titles and abstracts from the literature search were screened for potential eligibility by two
investigators (FC and SJK) independently, and in strict accordance with the inclusion and exclusion
criteria. In case of dispute, the key decision was made by a third investigator (AMP).
2.2. Data Management and Analysis
Data extraction was performed independently by two investigators (FC and SJK). The following
clinical information was extracted from each included study, if present: first author, year of publication,
study location, study design, age and characteristics of study population, definition of condition under
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consideration including severity, details of intervention and methodology (such as dosage, frequency,
route of administration, duration, and preparation of FMT material), primary and secondary outcome
measures and results, duration of follow-up, change in the microbiome after FMT, registered adverse
events (deaths, hospital admissions, and other adverse events as defined in each of the included
studies), and donor characteristics.
The primary outcome was change in symptoms related to pouchitis compared to before FMT
using the pouchitis disease activity index (PDAI) [32]. The definitions of clinical response (reduction in
PDAI ≥3) and clinical remission (reduction in PDAI ≥3 and total PDAI of <7) were used to evaluate
efficacy from studies reporting PDAI scores [7,33]. The use of the modified PDAI (mPDAI) and clinical
PDAI (cPDAI) was accepted [34]. It was accepted that the evaluation of symptoms was performed at
different timepoints after FMT.
Data was extracted as an intention-to-treat analysis, with dropouts assumed to be treatment
failures. In case of missing data or need for further clarification, the corresponding author of the
included study was contacted to retrieve further information. For the primary outcome of clinical
response and remission, pooled estimates were calculated for all patients treated with FMT.
2.3. Risk of Bias and Quality Assessment
The Cochrane risk of bias tool was used to assess for bias in randomized controlled trials (RCTs) [35].
Risk of bias in the cohort and case studies was assessed using the US National Heart, Lung, and Blood
Institute quality assessment tool [36], which has been used in other systematic reviews of FMT
treatment [37], with four weeks selected as cut-off for appropriate follow-up. Further description of
assessment of risk of bias and quality is available in the online Supplementary Materials, Tables S2–S4.
3. Results
The initial literature search identified 892 studies. After the removal of duplicates, 718 studies
underwent title and abstract screening. A total of 49 studies were full-text reviewed for eligibility.
Of these 40 were excluded for various reasons resulting in nine studies included in the qualitative and
quantitative synthesis (Figure 1).
Figure 1. PRISMA flow diagram of assessment of studies identified in the systematic review of fecal
microbiota transplantation (FMT) to treat chronic pouchitis.
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3.1. Patient Characteristics and Study Types
A total of 65 patients were treated with FMT in the nine included studies (Table 1). Most of
the included studies were case series, case reports or pilot studies. Only one clinical trial by
Herfarth et al. [23], randomized and blinded patients to receive either FMT or placebo. The definition
of chronic pouchitis varied among studies with no consistency (Table 2). Some studies used certain
values of PDAI [33,38] or mPDAI prior to inclusion [23], while other focused on recurrent need for
antibiotics (Table 2) [20,22,39].
Table 1. Patient characteristics, preparation of FMT and different treatment approaches of patients
treated with FMT for chronic pouchitis.
Total number of studies, n 9
Total patient population, n 65
Mean days of FMT treatment, days (range) 4.8 (1–14)
Mean delivered amount of stool by FMT, grams (range) (n = 51) 111.8 (11–525)
Mean follow-up, days (range) (n = 65) 87.6 (28–365)
Male/Female patients, n (n = 51) 22/29
Mean age of patients, years (range) (n = 51) 43.8 (22–77)
Time since restorative proctocolectomy, mean years (range) (n = 50) 10.3 (1–33)
Single/Multi donor FMT, n (n = 65) 56/9
Related/Unrelated donor, n (n = 65) 12/53
Upper/Lower administration/Both, n (n = 51) 13/32/6
Study type. Patients in RCT/Patients in non-RCT, n (n = 65) 6/59
FMT, fecal microbiota transplantation; RCT, Randomized Clinical Trial; n, number.
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Table 2. Clinical effects of FMT treatment to patients with chronic pouchitis.
Author
and Year
Study
Type Patient Population
Sample
Size
FMT
Treatment Route Dosage
Clinical
Response
(Reduction in
PDAI ≥3)
Clinical
Remission
(Reduction in
PDAI ≥3 and
Total of <7)
Endoscopic
Outcomes
Histologic
Outcomes Adverse Events Follow-Up
Fang et al.,
2016
Case
report
Chronic antibiotic
resistant pouchitis 1 Single FMT
Sigmoidoscopy
(delivered 40
cm into the
afferent limb
and pouch
body)
Stool mixed
with saline and
diluted to
250 mL
1/1 after 3
months (cPDAI
decreased from
6 at baseline
to 0)
1/1 after 3
months (cPDAI
decreased from
6 at baseline
to 0)
NA NA No reportedadverse events. 3 months
Herfarth
et al., 2019
RCT with
open-label
follow-up
Chronic antibiotic
dependent
pouchitis >4 weeks.
mPDAI ≥5
6 (FMT (4)
Placebo
(2)).
5 received
open-label
FMT
afterwards
Single
endoscopic
FMT followed
by daily oral
encapsulated
FMT for
2 weeks
Sigmoidoscopy
and oral
capsules
eFMT
(2 × 30 mL,
total of 24 g
donor stool)
and 6 capsules
daily consisting
of 4.2 g
donor stool
1/6 (Four
patients
receiving
primary FMT
and two
patients
receiving
open-label FMT
included)
1/6 (clinical
PDAI 1 and no
need for
antibiotics)
NA NA
No FMT related
safety events
were observed.
16 weeks
Kousgaard
et al., 2020
Cohort
(open-label
pilot
study)
Chronic pouchitis
(≥3 episodes of
pouchitis within
the last year)
9
14 days of daily
self-administered
FMT
Enema
20 g fecal
material diluted
in 100 mL saline
3/9 after four
weeks
3/9 after four
weeks
Mean ePDAI of
3.2 at baseline
decreased to 2.2
after four weeks
Mean hPDAI of
1.7 decreased to
1.0 after four
weeks
7/9 patients
reported adverse
events while
treated.
Abdominal
pain (5),
uncomfortable
(2), nausea (2),
fever (2), bloating
(1), dizziness (1),
and fatigue (1).
6 months
Landy
et al., 2015
Cohort
(pilot
study)
Chronic pouchitis
with current
PDAI ≥ 7
8 Single FMT Nasogastric
30 mL of
fecal-saline
solution
followed by
50 mL saline
2/8 after
4 weeks
0/8 after
4 weeks
Mean ePDAI of
5 at both
baseline and
after 4 weeks
Mean hPDAI of
3 at baseline
decreased to 2
after four weeks
Nausea (3),
bloating (2),
vomiting (1),
fever (1). All
transient (<24 h).
4 weeks
Nishida
et al., 2019
Case
series
Chronic pouchitis
with current
PDAI ≥7
3 Single FMT Colonoscopy
150–200 g
donor stool
mixed with
350–500 mL
sterile saline
1/3 after 8
weeks
0/3 after 8
weeks NA NA
No reported
adverse events. 8 weeks
Schmid
et al., 2017
Case
report
A severe flare of
pouchitis in a
patient diagnosed
with pouchitis one
year earlier
1
A total of three
FMTs at
baseline, after 5
and 9 weeks
Pouchoscopy
250 mL
fecal-saline
suspension
0/1 after 9
weeks
0/1 after 9
weeks NA NA
No reported
adverse events. 9 weeks
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Table 2. Cont.
Author
and Year
Study
Type Patient Population
Sample
Size
FMT
Treatment Route Dosage
Clinical
Response
(Reduction in
PDAI ≥3)
Clinical
Remission
(Reduction in
PDAI ≥3 and
Total of <7)
Endoscopic
Outcomes
Histologic
Outcomes Adverse Events Follow-Up
Selvig
et al., 2020
Cohort
(prospective
open-label
pilot
study)
Chronic pouchitis.
Prior endoscopic
evaluation
confirming
inflammation and
over 4 weeks of
symptoms
18 (7 of
the
18 patients
pre-treated
with
Rifaximin)
1 or 2 FMTs.
Single or
optional
re-treatment
Pouchoscopy.
Delivered to the
most proximal
point of
insertion
(proximal
pouch or
neo-terminal
ileum)
250/500 mL in
total derived
from 25/50 g
stool
1/11 after 4
weeks. Only 11
underwent
pouchoscopy at
4 weeks
1/11 after 4
weeks
Mean ePDAI of
3.38 at baseline
decreased to
3.36 after four
weeks
Mean hPDAI of
1.05 at baseline
increased to
1.36 after four
weeks
One patient
admitted to
hospital 8 days
after FMT
because of
abdominal pain
considered not
related to FMT.
One patient
diagnosed with
Crohn’s disease
at pouchoscopy
after four weeks,
which was
suspected in
advance. Minor
self-limiting
adverse events.
Discomfort (4),
flatulence (4),
bloating or
cramping (3),
fatigue (3), and
nausea (2).
12 months
Stallmach
et al., 2016
Prospective
open-label
pilot
study
Chronic antibiotics
resistant pouchitis
(three or more
cycles of
antibiotics)
5 1–7 FMTs
FMT to the
jejunum with
intervals of
3–4 weeks
275 mL fecal
saline
suspension
derived from
75 g stool
5/5 after last
FMT.
4/5 after last
FMT
Mean ePDAI of
3.8 at baseline
decreased to 1.2
after last FMT
Mean hPDAI of
3 at baseline
decreased to 1.2
after last FMT
Mild transient
fever and CRP
increase in one
patient.
3 months.
One patient
followed for
12 months
Steube
et al., 2017
Prospective
open-label
pilot
study
Chronic antibiotics
resistant pouchitis 14 2–4 FMTs
Nasojejunal or
capsule
application
delivered every
4 weeks
according to
treatment
outcome
NA
7/14. PDAI
scores however
not described.
Assessed
through
F-Calprotectin.
NA NA NA No reportedadverse events. 8 weeks
NA, not available; cPDAI, clinical Pouchitis Disease Activity Index; ePDAI, endoscopic Pouchitis Disease Activity Index; hPDAI, histologic Pouchitis Disease Activity Index;
FMT, Fecal Microbiota Transplantation; RCT, Randomized Controlled Trial; mPDAI, modified Pouchitis Disease Activity Index; F-Calprotectin, Fecal Calprotectin.
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3.2. Clinical Effects of FMT Treatment
The only included RCT, by Herfarth et al. [23], was prematurely stopped because of lower than
expected clinical remission rate and low donor engraftment. All of the four FMT treated patients and
the two placebo treated patients enrolled failed to respond and needed antibiotic rescue therapy after
study treatment. One patient (primarily receiving placebo) of the five patients treated in the following
open-label FMT extension phase achieved antibiotic free clinical remission.
The nine included studies did not evaluate the clinical effect of FMT at the same timepoint or
used the same methods to evaluate disease activity, why it was not possible to perform a proper
meta-analysis. One study did not evaluate treatment response through PDAI in all patients [40]
and one study used Fecal Calprotectin (F-Calprotectin) [20]. Hence, pooled estimates of the primary
endpoints of clinical response and remission could only be evaluated in 44 patients. Clinical response
was achieved in 14 (31.8%) out of 44 evaluated patients at various timepoints after FMT treatment,
while clinical remission was achieved in 10 (22.7%) out of 44 evaluated patients at various timepoints
after FMT.
Four of the included studies reported endoscopic and histologic PDAI (ePDAI and hPDAI) with a
trend of small improvements in two of the studies [22,39], while no change or minor beneficial changes
were observed in the other two (Table 2) [38,40].
Some studies also evaluated specific symptoms. Selvig et al. [40], reported improvement in
number of bowel movements and abdominal pain, while Schmid et al. [21], reported transiently
improved bloating and pain with stool urgency and frequency remaining grossly unchanged.
F-Calprotectin is routinely used as a marker of disease activity in patients with IBD and pouchitis
and is found to be correlated to change in symptoms [41]. In the studies where the patients’ symptoms/
PDAI improved, F-Calprotectin also decreased [20,22]. F-Calprotectin was stable or decreased
insignificantly in the studies finding no or minor beneficial effects after treatment [23,40].
3.3. Safety/Adverse Events
No deaths, hospital admissions or serious adverse events considered related to FMT were
reported. Minor self-limiting adverse events were reported in several studies [22,38–40]. Most of these
were gastrointestinal (nausea, abdominal pain, or bloating), but fever, dizziness, fatigue and feeling
uncomfortable were also reported (Table 2).
3.4. Microbiome Changes after FMT
Six studies assessed if bacterial alpha diversity increased in fecal or mucosal samples after FMT
treatment. In five studies, no significant changes were observed [23,33,38–40]. This was true in
studies using both single and multiple FMT treatments [33,38–40]. In the study by Herfarth et al.,
increased fecal bacterial diversity after FMT was concluded to be mainly caused by the cessation of
antibiotic treatment 24 h prior to FMT [23]. Steube et al., found a significant increased bacterial alpha
diversity in patients with improved clinical outcomes after FMT treatment [20]. However, an increased
bacterial alpha diversity was not necessarily correlated to improved clinical outcomes, and some
patients increased their diversity without clinical improvement.
Seven studies analysed whether the recipients’ microbiota resembled the donors’ microbiota after
treatment [20,22,23,33,38–40]. Interestingly, increased resemblance to the donors’ microbiota after
treatment was in three studies correlated to beneficial clinical effect with significant changes seen only
in patient who improved clinically [22,23,40].
Four studies reported changed abundance of certain specific bacteria after FMT [20,22,38,40].
Species such as Ruminococcaceae and Lachnospiraceae family and genus Faecaelibacterium were
enriched as sign of engraftment and others such as Escherichia coli decreased in abundance in recipients
after FMT treatment. None of these studies reported a correlation to clinical effect of engraftment or
decreased abundance of specific bacteria.
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3.5. Preparation and Delivery of FMT Material
Most of the included studies used FMT material from unrelated donors [20,22,23,38,40], but in
three studies FMT material from relatives were used (Table 3) [21,33,38]. Only the study by Kousgaard
et al., used FMT from multiple donors [39]. The delivered FMT material varied greatly in the
preparation method and delivery approach among the included studies (Table 3). Five studies
used fresh fecal material delivered 4–6 h prior to treatment [21,22,33,38], while other used frozen
material [22,23,39,40]. The FMT material was delivered to the recipients through both upper [20,22,38]
and lower endoscopically delivery [21,23,33,40,42], and delivery through capsules [20,23], or enemas [39]
(Table 2). The use of different types of bowel cleansing prior to FMT was reported in several of the
studies delivering FMT through lower endoscopy [21,33,40].
The length of FMT treatment also varied between the studies from a single FMT [33,38,42], to up to
two weeks of daily treatment [23,39]. Hence, the total delivered FMT dose varied in between the studies.
The lowest amount of 30 mL fecal–saline solution was reported in the study by, Landy et al. [38],
and the highest amount of a total of 1925 mL FMT material derived from 525 g stool delivered to one
of the patients during seven FMTs was reported in the study by Stallmach et al. [22].
Two studies reported stopping antibiotic treatment 24–48 h prior to FMT treatment [23,42],
while seven of the 18 patients in the study by Selvig et al. [40] were pre-treated with rifaximin for
a total of five days, beginning eight days prior to FMT. The patients in the included studies were
in general permitted to continue concomitant treatment while receiving FMT including biological
treatment, [40] while antibiotics and probiotics were not permitted [39,42].
3.6. Quality Assessment of Studies and Risk Of Bias
Six studies were rated as having fair to poor quality due to high risk of bias and small sample
size. Only one RCT, by Herfarth et al. [23], with six included patients was included. Most of the other
studies were case series and case reports with no predefined treatment outcomes or inclusion criteria
(online Supplementary Materials, Tables S2–S4).
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Table 3. Preparation and delivery of FMT material.
Author and Year Donor(s) Fresh/Frozen FMT Preparation Concomitant Treatment Pre-Treatmentwith Antibiotics Single/Multi-donor Bowel Cleansing
Fang et al., 2016 Unrelated donor Fresh Stool mixed with sterile saline anddiluted to 250 mL
The patient was off his usual
antibiotics during the entire
follow-up period but
continued antidiarrheal
medication.
Antibiotics
stopped 48 h
before FMT
Single No
Herfarth et al., 2019
Unrelated donor with
high butyrate
production
Frozen
Stool bank provided FMT for
endoscopic administration, FMT
capsules and matching placebos
NA
Antibiotics
stopped 24 h
before FMT
Single NA
Kousgaard et al., 2020 Unrelated Frozen
20 g stool mixed with 100 mL
sterile water, blended and filtered,
10% glycerol
Concurrent therapies were
permitted if stable with
exception of antibiotics,
probiotics, and biologic
treatment.
Antibiotics
stopped 7 days
before FMT
Multi-donor (5
donors) No
Landy et al., 2015 Relative/partner (6) oranonymous (2)
Fresh (less than 6 h
prior to FMT)
30 g of stool was homogenized
with a household blender in 50 mL
of 0.9% saline and filtered through
sterile gauze to produce a
fecal-saline solution
Night before the procedure
the recipient was treated with
a proton pump inhibitor
(Omeprazole 20 mg).
NA Single NA
Nishida et al., 2019 Second degreerelatives
Fresh (less than 4 h
prior to FMT)
150–200 g donor stool mixed with
350–500 mL sterile saline and
filtered through gaze
NA NA Single Polyethylene glycolsolution
Schmid et al., 2017 Patient’s son Fresh (less than 6 hprior to FMT)
A fresh stool sample diluted with
500 mL saline and filtered
through gaze
NA NA Single Enemas
Selvig et al., 2020 Unrelated Frozen 25 g of stool mixed with saline to a250 mL fecal suspension
Accepted with antibiotics as
exception. Three patients
continued biologic treatment.
7/18 patients
received 5 days of
550 mg Rifaximin
beginning 8 days
prior to treatment
Single (from 11
different donors)
Magnesium citrate a day
before FMT and
phosphate enema at day
of FMT
Stallmach et al., 2016 Unrelated Fresh (first FMT)and frozen
150 g stool mixed with 400 mL
saline. Then filtered and separated
in two. The first immediately
delivered to the patient and the
second stored at −80 ◦C
NA NA Single (from 2different donors) No
Steube et al., 2017 Unrelated NA NA NA NA Single (from 3different donors) NA
NA, not available; FMT, Fecal Microbiota Transplantation.
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4. Discussion
4.1. Main Findings
Only nine studies have investigated the effects of FMT on pouchitis symptoms in a total of
65 patients with chronic pouchitis. There is a scarceness of high-quality studies; hence, the true
effect of the treatment remains unclear. The only RCT included in this systematic review [23],
was prematurely stopped because of low clinical efficacy and low donor microbial engraftment.
Some of the included studies reported high response and remission rates [20,22], while others found
no or minor beneficial effect of the treatment [21,23,38,40]. The calculated proportions of patients
achieving clinical response and remission of 31.8% and 22.7%, respectively, must be interpreted with
precaution since a great heterogeneity between the studies exist and the low quality of evidence in
most studies. Hence, this systematic review gives no clear answers of whether FMT is beneficial in
patients with chronic pouchitis, but points towards the need for new well-designed controlled studies.
4.2. Strengths and Limitations
This systematic review is the first to collect data on clinical outcomes from all published studies
treating chronic pouchitis patients with FMT. A systematic review on this topic is important, as studies
on FMT to chronic pouchitis only have included a very limited number of patients each. The review
gives the first full overview of both the clinical indications of treatment, the different treatment
approaches, the clinical efficacy, safety of treatment and microbiome changes caused by the treatment.
There are also limitations. The quality of evidence in most of the included studies were evaluated
as fair or poor, and only one RCT was included. Furthermore, there was great differences in definition
of disease activity both prior to and after treatment. The timepoint where the effect of treatment
was assessed also varied among studies. Further, all included studies had different approaches to
preparation, delivery and length of FMT treatment, which make interpretation of the overall effects
and approaches of treatment very difficult.
4.3. Clinical Efficacy of Treatment
Some of the included studies found improved clinical outcomes with decreased symptom
scores [22,39], and lowered F-Calprotectin [20], which indicate that some patients with chronic
pouchitis may benefit from treatment with FMT. Furthermore, Lan et al. reported potential beneficial
effects of FMT for treating Clostridioides difficile infection in patients with ileal pouches [43]. The authors
reported that FMT treatment of rCDI in patient with ileal pouches, also improved pouchitis symptoms
besides the elimination of rCDI symptoms. A further indication of a potential beneficial effect is the
finding of a correlation between engraftment of donor microbiome and improved clinical outcomes in
the recipients, reported in several of the studies included in the review [20,22,23,40]. Several studies
found a missing or low clinical efficacy in the majority of the patients [21,23,38,40], indicating that not
all patients might benefit from the FMT treatment or that the treatment should be delivered differently.
In UC, where gut dysbiosis also has been linked to disease activity [44], FMT treatment has been
found superior to placebo treatment in recent RCTs, although the treatment protocols varied in between
the studies [18,45–47]. The pooled clinical response and remission rates of the RCTs of 49% and 28%,
respectively [48], also indicate that not all UC patients benefit from the treatment. The focus is now to
predict which patients that may benefit from FMT treatment in both UC and other conditions [49,50].
The general definition of chronic pouchitis is confirmed pouchitis by PDAI with more than four
weeks disease activity [7]. In this review, we choose to get a full overview of the FMT treatment and
treatment indications. Hence, we included both studies that used antibiotic refractory/dependent
pouchitis and several episodes of pouchitis within the last year as inclusion criteria. This makes it almost
impossible to transfer conclusions regarding treatment efficacy to all patients with chronic pouchitis.
Furthermore, not all studies evaluated the patients with a full PDAI score [20,23,42]. The PDAI
score is an 18-point index to assess pouchitis activity, based on clinical symptoms, endoscopically
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and histologically evaluation and is the most commonly used tool to evaluate pouchitis disease
activity [7,51]. The use of the modified scores mPDAI [34] (only including clinical symptoms and
endoscopic evaluation) and cPDAI (only including clinical symptoms), makes it easier to include
patients in studies because endoscopies and biopsies are not needed, but decreases the comparability
of the results. Therefore, we urge that future studies use a full PDAI score before and after treatment
with FMT. We also recommend that the commonly used definitions of clinical response (reduction in
PDAI ≥3) and remission (reduction in PDAI ≥3 and PDAI of <7) are used in future studies [7].
Further we recommend that evaluation of the patients should be after four weeks, since a
beneficial clinical effect of FMT treatment has been reported at this timepoint in several of the included
studies [38,39,52].
4.4. Safety
Only self-limiting transient mainly gastrointestinal adverse events were reported as related to FMT
in the included studies, which are in line with data from FMT treatment to other indications [53,54].
In general, FMT treatment is considered safe, when the current international recommendations
considering donor screening are followed [53,55]. A recent death of an immunocompromised patients
announced in June 2019, by the Federal Drug Agency (FDA) in the Unites States, following treatment
with FMT capsules, where extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli were
transferred from the donor to the recipient, indicates that donor screening protocols must be elaborate
to avoid the transfer of multi-drug resistant microorganisms [56]. No cases of transferred diseases
were reported in any of the included studies. The long-term safety of FMT is not fully investigated.
Results from patients with rCDI treated with FMT, which are often multi-morbid and frail, does not
indicate long-term adverse events [54,57]. FMT to chronic pouchitis possibly requires several FMT
treatments to achieve clinical remission similar to UC [18,45,46,48,58], whereas usually one FMT is
sufficient to treat rCDI [59]. It is therefore of great importance that future studies investigate the
long-term adverse events after FMT to patients with chronic pouchitis.
4.5. Microbiome Changes
Whether the changed gut microbiome of patients with chronic pouchitis is a cause or a
consequence of the disease is not fully understood [8]. Furthermore, patients with chronic
pouchitis often have received several antibiotic treatments, which also changes the microbiota of
the pouch [12]. The results from some of the included studies using 16 S sequencing indicate that
there is a correlation between improved clinical outcomes and changes in the gut microbiome with
increased bacterial alpha diversity or increased resemblance to the healthy donor microbiota after
FMT [20,22,23,40], while Herfarth et al. [23], terminated their RCT because of low clinical efficacy and
low donor engraftment.
In cases of treating rCDI and inducing clinical remission in UC the following microbiome
changes have been correlated to success of treatment after FMT; increased bacterial diversity [60],
increased resemblance of the recipients microbiome to the donors [46], and changes in the amount
of certain potentially harmful or beneficial bacteria [61]. Hence, it makes sense to design FMT
interventions in doses appropriate for such microbiome changes in future trials of chronic pouchitis.
The role of other parts of the gut microbiome than bacteria in chronic pouchitis has not been
reported [8]. Knowledge from other diseases indicates the important roles of fungi and bacteriophages
in correlation to the effect of FMT [62,63]. Thus, future trials investigating the effect of FMT on other
parts of the gut microbiome are important to increase the understanding of the correlation between the
microbiome and chronic pouchitis. Furthermore, none of the included studies used next-generation
sequencing techniques, such as shotgun metagenomics [64], which are being increasingly used in the
evaluation of the effects of FMT in the treatment of other conditions [65]. We recommend future studies
to use deeper microbiome analysis, not limited to 16 S sequencing, to advance our understanding of
the changes in the microbiome caused by FMT.
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4.6. FMT Material: Donors
Results from studies using FMT treatment to UC and irritable bowel syndrome (IBS) have
indicated that certain donors are more "superior" than others to induce beneficial clinical effects in
patients [46,49,66]. The gut dysbiosis of chronic pouchitis is probably different from the gut dysbiosis
associated to other conditions: hence, a good donor in treatment of chronic pouchitis may be different
than for other conditions [8]. Neither in chronic pouchitis or other diseases there is a full understanding
of what defines an ideal donor, though the understanding is increasing [60].
In the included RCT by Herfarth et al. [23], which found no beneficial effect of FMT, a donor
delivering stools with a high butyrate content was used. Butyrate has been correlated to high microbial
diversity and better therapeutic response in FMT trials treating other conditions [67–70]. Three of
the included studies used a close relative as stool donor [21,33,38], which is not considered inferior,
but with the establishment of stool banks, treatment with stool from close relatives will probably
become less prevalent [71]. Patients with a pouch without episodes of pouchitis possibly have a healthy
microbiome preventing pouchitis and could maybe be ideal donors.
We encourage future studies to continue the assessment of whether certain characteristics of the
donor microbiome are associated with beneficial effects.
4.7. FMT Material: Preparation and Delivery
In general, the included studies varied in both the preparation of FMT material, amount of stool
used for treatment, and whether the treatment was given shortly after donation or if frozen stored FMT
material was used. In the treatment of UC and IBS, where a dysbiotic gut microbiome probably should
be changed to a eubiotic through engraftment of beneficial microorganisms from healthy donors,
higher doses or multiple deliveries are more effective than lower doses or single FMT treatment [48,66].
We propose future trials to use multiple FMT treatment based upon this knowledge.
4.8. FMT Material: Route of Administration
In spite of the anatomic location of the diseased tissue in the lower gastrointestinal tract of chronic
pouchitis, several of the included studies used upper administration of FMT material through either
capsules [20,23], or upper endoscopy [20,22]. The fact that some of these studies found positive
clinical effects indicate that both upper and lower administration may have beneficial effect. For other
conditions located in the lower part of the gastrointestinal tract, such as IBS and UC, a treatment with
FMT delivered through upper administration has also been found successful [72,73]. Future studies
should investigate if a certain route is more beneficial than others.
4.9. Perspectives
As FMT treatment has received a more widespread use and the establishment of stool banks are
emerging in many countries [74,75], we hope that more well-designed controlled trials investigating
the effects of FMT in chronic pouchitis will be performed. This in spite of the disappointing clinical
results from the only RCT published by Herfarth et al. in 2019 [23], possibly due to low donor
microbial engraftment. Chronic pouchitis patients have severely impaired health related quality of
life [76], and there is strong need of new treatment options. Future well-designed controlled trials
using clearly defined disease definitions, comparing the effects of FMT treatment with either placebo,
FMT delivered through another route or FMT with a different dose or duration, will be necessary to
move the understanding of the true effect of FMT treatment in chronic pouchitis forward.
5. Conclusions
The effects of fecal microbiota transplantation on symptoms of chronic pouchitis are not established,
though some studies show promising results. The treatment appears safe, when guidelines for donor
screening are followed. Future controlled studies investigating safety, dose, duration, preparation of
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FMT, administration route, and concomitant treatments are needed to establish whether FMT can be a
part of the treatment of chronic pouchitis.
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